Icon Advisers Inc. Co. reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 48.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 28,600 shares of the medical research company’s stock after selling 26,900 shares during the quarter. Icon Advisers Inc. Co.’s holdings in Edwards Lifesciences Corporation were worth $3,126,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in EW. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences Corporation by 2.0% in the second quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock worth $2,453,311,000 after acquiring an additional 406,901 shares during the period. BlackRock Inc. grew its stake in shares of Edwards Lifesciences Corporation by 0.8% in the second quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock worth $1,668,309,000 after acquiring an additional 105,819 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Edwards Lifesciences Corporation by 161.7% in the second quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after acquiring an additional 3,277,726 shares during the period. American Century Companies Inc. grew its stake in shares of Edwards Lifesciences Corporation by 7.0% in the third quarter. American Century Companies Inc. now owns 2,224,010 shares of the medical research company’s stock worth $243,107,000 after acquiring an additional 144,701 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Edwards Lifesciences Corporation by 13.3% in the second quarter. Wells Fargo & Company MN now owns 2,119,260 shares of the medical research company’s stock worth $250,581,000 after acquiring an additional 248,293 shares during the period. Institutional investors and hedge funds own 82.16% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/icon-advisers-inc-co-has-3-13-million-holdings-in-edwards-lifesciences-corporation-ew/1722001.html.

In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total transaction of $594,395.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $112.45, for a total transaction of $3,699,605.00. The disclosure for this sale can be found here. Insiders have sold 191,440 shares of company stock worth $20,645,937 in the last ninety days. Insiders own 2.13% of the company’s stock.

EW has been the subject of a number of research analyst reports. Royal Bank Of Canada reiterated a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and issued a $130.00 price target (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Canaccord Genuity reiterated a “buy” rating and issued a $135.00 price target (down from $155.00) on shares of Edwards Lifesciences Corporation in a research note on Wednesday, October 25th. Jefferies Group LLC raised their price objective on shares of Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $132.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, September 1st. Seven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $125.17.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded down $0.71 during trading hours on Thursday, reaching $108.81. 835,900 shares of the company’s stock traded hands, compared to its average volume of 1,630,647. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76. Edwards Lifesciences Corporation has a twelve month low of $81.12 and a twelve month high of $121.45. The stock has a market capitalization of $23,176.61, a P/E ratio of 30.34, a P/E/G ratio of 1.96 and a beta of 0.46.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The firm had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $833.85 million. During the same period in the prior year, the firm earned $0.68 EPS. Edwards Lifesciences Corporation’s revenue for the quarter was up 11.1% compared to the same quarter last year. research analysts expect that Edwards Lifesciences Corporation will post 3.75 EPS for the current year.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.